| Project/Area Number |
15K15183
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Applied pharmacology
|
|---|
| Research Institution | Osaka University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
FUJIWARA TOSHIYOSHI 岡山大学, 大学院医歯薬学総合研究科, 教授 (00304303)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2016: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | 腫瘍溶解性ウイルス / 癌関連線維芽細胞 / アポトーシス / ネクロプトーシス / 腫瘍 / TGF-b |
|---|
| Outline of Final Research Achievements |
Cancer-associted fibroblasts (CAF) are an important target for cancer therapy because CAF are involved in growth, survival, and mallignant alteration of cancer cells. In this study, we examined whether reovirus kills CAF. Reovirus reduced the viabilities of mouse CAF isolated from subcataneous tumors to 50-60%, indicating that reovirus mediates cell killing effects on mouse CAF. On the other hand, viabilities of normal mouse CAF were not significantly altered by reovirus. In addition, apoptotic CAF were detected in the tumor following intravenous administration of reovirus.
|
